Preclinical development of dengue vaccine announced

Advanced BioScience Laboratories, Inc., and Hawaii Biotech, Inc., announced on May 25 that they will be joining forces with the National Institute of Allergy and Infectious Diseases for preclinical development of a dengue vaccine.

Officials with Hawaii Biotech said that they plan to begin the first phase of a human clinical study with its tetravalent dengue vaccine candidate later this year. The sub-unit vaccine will be designed with high resistance to all four of the native viral antigens, which officials believe will provide balanced immunity.

Advanced BioScience, through a contract from the National Institute of Allergy and Infectious Diseases, will oversee the manufacturing and testing of all supplies.

“In preparing to evaluate our tetravalent dengue vaccine in the clinic, we looked for a contract research organization with deep experience in viral vaccine development,” Elliot Parks, Hawaii Biotech's president and CEO, said. “ABL is that organization. Its long-standing and successful relationship with NIAID has led to discoveries that have advanced our understanding of other viral diseases and led to the development of safe and efficacious vaccines.”

Parks said that the three-way partnership will save Hawaii Biotech up to $2 million and will allow the company to move along more rapidly than it could alone.

Advanced BioScience Laboratories president and CEO Dr. Dr. Thomas VanCott said he is also excited about the partnership.

“We are making significant progress together and are proud to be part of this critical effort to bring this dengue virus vaccine candidate to the clinic,” VanCott said.